Transchem
BSE: TRANSCHEM · Pharmaceuticals
Snapshot
Unlock Transchem's vital signs
Growth · Profitability · Valuation · Strength · Conviction
Company Overview
Business
Transchem Ltd was historically engaged in mushroom production and processing through a 100% Export Oriented Unit. Following the cessation of these operations, the company has monetised its manufacturing assets and is currently seeking new business opportunities.
Business Model
The company currently operates as a cash-rich entity without active manufacturing operations. It generates income primarily through short-term treasury investments while evaluating potential new business ventures.
Management Commentary
Management is actively exploring new investment opportunities to deploy the capital realised from the sale of its former manufacturing plant. The company remains in a transition phase while maintaining its funds in short-term financial instruments.
Growth Outlook
Future growth is entirely dependent on the successful identification and acquisition of a new business line. The company's current focus is on capital preservation and strategic evaluation of potential ventures.
Key Risks
- Business Continuity Risk. The company lacks an active core business operation, creating uncertainty regarding its long-term viability.
- Capital Allocation Risk. There is a risk that the company may fail to identify or execute a profitable new business opportunity, leading to the erosion of existing capital.
- Regulatory and Compliance Risk. As a listed entity without active operations, the company faces ongoing scrutiny regarding its regulatory compliance and maintenance of its listing status.
Start your research today
Unlock AI insights, financials, peers and live data on Transchem and 5,000+ companies — free.
Key Metrics
REVENUE
₹0 Cr
TTM · standalone
NET PROFIT
₹7 Cr
TTM · standalone
EPS
₹5.49
TTM · standalone
RETURN ON EQUITY
8.3%
TTM · standalone
RETURN ON CAPITAL EMPLOYED
10.6%
TTM · standalone
P/E
75.6x
Q1 FY27 · standalone
EV/EBITDA
53.0x
Q1 FY27 · standalone
EBITDA MARGIN
177.7%
TTM · standalone
NET PROFIT MARGIN
30.2%
Q4 FY25 · standalone
DEBT TO EQUITY
0.0x
Q1 FY27 · standalone
Peers · Pharmaceuticals
| Company | Mkt Cap | P/E | EV/EBITDA | Rev Gr YoY | EBITDA Mgn | ROE | ROCE | 1Y Return |
|---|---|---|---|---|---|---|---|---|
TranschemTRANSCHEM | ₹502 Cr | 75.62 | 52.99 | -100.0% | 177.7% | 8.3% | 10.6% | +600.8% |
Influx Health.INFLUX | ₹655 Cr | — | — | — | 20.0% | — | — | +51.5% |
Albert DavidALBERTDAVD | ₹501 Cr | 21.67 | 13.19 | 11.4% | 11.0% | 5.8% | 7.5% | +10.3% |
Haleos Labs LimitedHALEOSLABS | ₹457 Cr | 28.51 | 12.83 | -3.1% | 13.6% | 7.4% | 10.3% | — |
Medicamen BiotecMEDICAMEQ | ₹434 Cr | 43.00 | 19.76 | 24.7% | 11.3% | 4.1% | 6.2% | +5.9% |
Jenburkt Pharmaceuticals LimitedJENBURPH | ₹420 Cr | 12.30 | 8.20 | — | 30.0% | 16.7% | 21.5% | -15.2% |
As of Q1 FY27
Financials
Transchem
BSE: TRANSCHEM · Pharmaceuticals
Snapshot
Unlock Transchem's vital signs
Growth · Profitability · Valuation · Strength · Conviction
Company Overview
Business
Transchem Ltd was historically engaged in mushroom production and processing through a 100% Export Oriented Unit. Following the cessation of these operations, the company has monetised its manufacturing assets and is currently seeking new business opportunities.
Business Model
The company currently operates as a cash-rich entity without active manufacturing operations. It generates income primarily through short-term treasury investments while evaluating potential new business ventures.
Management Commentary
Management is actively exploring new investment opportunities to deploy the capital realised from the sale of its former manufacturing plant. The company remains in a transition phase while maintaining its funds in short-term financial instruments.
Growth Outlook
Future growth is entirely dependent on the successful identification and acquisition of a new business line. The company's current focus is on capital preservation and strategic evaluation of potential ventures.
Key Risks
- Business Continuity Risk. The company lacks an active core business operation, creating uncertainty regarding its long-term viability.
- Capital Allocation Risk. There is a risk that the company may fail to identify or execute a profitable new business opportunity, leading to the erosion of existing capital.
- Regulatory and Compliance Risk. As a listed entity without active operations, the company faces ongoing scrutiny regarding its regulatory compliance and maintenance of its listing status.
Start your research today
Unlock AI insights, financials, peers and live data on Transchem and 5,000+ companies — free.
Key Metrics
REVENUE
₹0 Cr
TTM · standalone
NET PROFIT
₹7 Cr
TTM · standalone
EPS
₹5.49
TTM · standalone
RETURN ON EQUITY
8.3%
TTM · standalone
RETURN ON CAPITAL EMPLOYED
10.6%
TTM · standalone
P/E
75.6x
Q1 FY27 · standalone
EV/EBITDA
53.0x
Q1 FY27 · standalone
EBITDA MARGIN
177.7%
TTM · standalone
NET PROFIT MARGIN
30.2%
Q4 FY25 · standalone
DEBT TO EQUITY
0.0x
Q1 FY27 · standalone
Peers · Pharmaceuticals
As of Q1 FY27